Tradestie Institutional Equity Comparison Engine

AMS vs DXR โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

DXR Overall Edge

DXR Captures Institutional Edge (2โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Daxor Corporation Common Stock (DXR) driven by superior Growth & Margin, Momentum & Technical while AMS counters with relative strength in Valuation. Fundamentally, AMS trades at 44.6x Forward P/E with -7.4% operating margin (+19.2% YoY revenue) versus DXR at 64.5x Forward P/E and -5894.3% operating margin (+25.5% YoY). In options structure, AMS sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against DXR sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner AMS
AMS 44.6x vs DXR 64.5x Fwd P/E
Growth & Margin Winner DXR
Op Margin -7.4% vs -5894.3% ยท YoY +19.2% vs +25.5%
Momentum & Technical Winner DXR
1Y -52.2% vs -38.3% ยท 52W Pos 6% vs 2%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
AMS NYSE American
American Shared Hospital Services
Services-Medical Laboratories
$1.07
-0.93% 1D
Market Cap $7.2M
1M Return -16.41%
1Y Return -52.23%
Forward P/E 44.6x
Unified AI Score
33.8 / 100 SELL
Tech 24.0 Fund 38.0 Flow 50.0 Mom 30.0
DXR NASDAQ
Daxor Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$8.36
-1.47% 1D
Market Cap $49.5M
1M Return -16.87%
1Y Return -38.29%
Forward P/E 64.5x
Unified AI Score
52.2 / 100 HOLD
Tech 52.0 Fund 59.0 Flow 50.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: AMS -52.23% DXR -38.29% Spread: +18.96 pp (DXR Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
AMS TTM Op. Margin: -7.4% DXR TTM Op. Margin: -5894.3%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AMS vs DXR. Trailing 12-month operating profitability (AMS -7.4% vs DXR -5894.3%) and valuation multiples (AMS 44.6x vs DXR 64.5x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: AMS (3) vs DXR (7)
Institutional Metric AMS DXR Criterion Row Winner
Market Capitalization Scale $7.2M $49.5M Larger Scale DXR
Trailing P/E Ratio Valuation 44.6x 7.7x Lower Multiple DXR
Forward P/E Ratio Valuation 44.6x 64.5x Lower Multiple AMS
Revenue Growth (YoY) Growth +19.2% +25.5% Higher Growth DXR
Operating Margin (TTM) Profitability -7.4% -5894.3% Higher Margin AMS
Net Profit Margin Profitability -5.8% 19861.4% Higher Margin DXR
Return on Equity (ROE) Capital Efficiency -12.1% 14.2% Higher ROE DXR
52-Week Range Position Momentum 6% ($1โ€“$2) 2% ($8โ€“$15) Stronger Trend AMS
Beta / 30D Volatility Risk Regime 0.18ฮฒ ยท 46% Vol 0.28ฮฒ ยท 32% Vol Lower Realized Risk DXR
Unified Institutional Score Composite Signal 33.8 / 100 (SELL) 52.2 / 100 (HOLD) Higher Composite DXR

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full AMS vs DXR Buy Guide
AMS UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live AMS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
DXR UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live DXR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither AMS nor DXR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.